NCT06263920 Neurofrailty: A Study of Late-onset Epilepsy and Its Associations
| NCT ID | NCT06263920 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Lancashire Teaching Hospitals NHS Foundation Trust |
| Condition | Late Onset Epilepsy |
| Study Type | OBSERVATIONAL |
| Enrollment | 360 participants |
| Start Date | 2022-05-05 |
| Primary Completion | 2027-01-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 360 participants in total. It began in 2022-05-05 with a primary completion date of 2027-01-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
There is not much known about why some people develop seizures in adulthood, but some researchers think that it might be a warning from the body to highlight something may be wrong with the brain. A small number of people with first seizure in adulthood go on to experience problems like stroke or dementia later in life. However, stroke and dementia are common diseases, so it is not know whether there is a real association between these conditions. When people develop their first seizure in adult life, this is sometimes called Late-Onset Epilepsy. The NeuroFrailty study, will observe 'brain health' over the years following the onset of a seizure, to provide more information about people with these kinds of seizures.
Eligibility Criteria
Inclusion criteria for case participants includes: * diagnosis of LOE or first seizure after the age of 18. * diagnosis confirmed or established at a tertiary neurology centre. * sequential cases will be used; in the unlikely event that eligible cases outstrip capacity, an annual cap of the first 150 patients per year per cohort will be used. Inclusion criteria for control participants includes: * established diagnosis of migraine. * with or without therapeutic medications with antiepileptic properties. Exclusion Criteria Exclusion criteria for case participants includes: * a 'lesional' attributable cause for seizures including malignancy, stroke (excluding transient ischaemic attack), hypoxic brain injury, trauma, vascular or congenital abnormality of likely aetiological significance. * people with migraine or headache syndrome can be included in case group - the presence or absence of a seizure syndrome is mutually exclusive between case and control groups, not the presence or absence of migraine. Exclusion criteria for control participants includes: * diagnosis of epilepsy or confirmed seizure. * 'lesional' attributable cause for seizures including malignancy, stroke (excluding transient ischaemic attack), hypoxic brain injury, trauma.
Contact & Investigator
Jasmine Wall, MB BChir
PRINCIPAL INVESTIGATOR
University of Lancaster
Frequently Asked Questions
Who can join the NCT06263920 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Late Onset Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06263920 currently recruiting?
Yes, NCT06263920 is actively recruiting participants. Contact the research team at jasmine.wall@lthtr.nhs.uk for enrollment information.
Where is the NCT06263920 trial being conducted?
This trial is being conducted at Preston, United Kingdom.
Who is sponsoring the NCT06263920 clinical trial?
NCT06263920 is sponsored by Lancashire Teaching Hospitals NHS Foundation Trust. The principal investigator is Jasmine Wall, MB BChir at University of Lancaster. The trial plans to enroll 360 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.